# Kerala Ayur (NSE: KERALAYUR) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/KERALAYUR · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹254 Cr, it ranks 2134th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −147.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹35 Cr (+10.9% year on year) and net profit −₹7 Cr, on a consolidated basis. Promoters held 35.61% of the company as of 30 Jun 2026; 20.35% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹254 Cr |
| ROE | −147.0% (FY25) |
| ROCE | −20.0% (FY25) |
| Debt to equity | 6.95 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹35 Cr | +10.9% | −₹7 Cr | — | −₹5.83 |
| Q3 FY26 | ₹33 Cr | +5.9% | −₹5 Cr | — | −₹3.69 |
| Q2 FY26 | ₹35 Cr | +9.4% | −₹6 Cr | −274.2% | −₹7.23 |
| Q1 FY26 | ₹29 Cr | −0.1% | ₹2 Cr | +341.3% | ₹1.92 |
| Q4 FY25 | ₹31 Cr | +14.3% | −₹15 Cr | −15,470.0% | −₹13.68 |
| Q3 FY25 | ₹31 Cr | +12.4% | −₹3 Cr | — | −₹2.40 |
| Q2 FY25 | ₹32 Cr | +21.7% | ₹4 Cr | — | ₹0.30 |
| Q1 FY25 | ₹29 Cr | +20.4% | ₹0 Cr | — | ₹0.33 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹120 Cr | −₹14 Cr |
| FY24 | ₹108 Cr | −₹1 Cr |
| FY23 | ₹93 Cr | −₹0 Cr |
| FY22 | ₹80 Cr | ₹2 Cr |
| FY21 | ₹62 Cr | −₹5 Cr |
| FY20 | ₹77 Cr | ₹4 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 35.61%
- Foreign institutions: 0.17%
- Domestic institutions: 0.04%
- Non-institutions: 64.19%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Espire Hospital](https://app.pivotnow.in/stock/ESPIRE) | — | ₹274 Cr | — | — |
| [Zenotech Labs](https://app.pivotnow.in/stock/ZENOTECH) | — | ₹270 Cr | — | — |
| [Everest Organic](https://app.pivotnow.in/stock/EVERESTO) | — | ₹262 Cr | — | — |
| [Gennex Labs](https://app.pivotnow.in/stock/GENNEX) | — | ₹254 Cr | — | — |
| [Nath Bio-Genes (India)](https://app.pivotnow.in/stock/NATHBIOGEN) | ₹132.60 | ₹252 Cr | 6.3 | — |
| [BDH Industries](https://app.pivotnow.in/stock/BDH) | — | ₹252 Cr | — | — |

## Questions and answers

### What is the market cap of Kerala Ayur?

Kerala Ayur's market capitalisation is ₹254 Cr (₹254 Cr) at the 22 Oct 2026 close, ranking 2134th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Kerala Ayur?

Return on equity was −147.0% in FY25 and return on capital employed was −20.0% in FY25 (consolidated figures).

### Is Kerala Ayur a debt-free company?

No. Kerala Ayur's debt-to-equity ratio was 6.95 in FY25, with total debt of ₹18 Cr.

### What were Kerala Ayur's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Kerala Ayur reported revenue of ₹35 Cr, +10.9% year on year, and net profit of −₹7 Cr.

### What is the shareholding pattern of Kerala Ayur?

As of 30 Jun 2026: promoters 35.61%, foreign institutions 0.17%, domestic institutions 0.04%, non-institutions 64.19%. 20.35% of promoter shares were pledged.

### Who are Kerala Ayur's competitors?

The listed Pharma & Healthcare companies closest to Kerala Ayur by market cap are Espire Hospital, Zenotech Labs, Everest Organic, Gennex Labs, Nath Bio-Genes (India) and BDH Industries.

### Is Kerala Ayur a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Kerala Ayur's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KERALAYUR against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.